Burosumab - Kyowa Hakko Kirin Pharma/Ultragenyx Pharmaceutical
At a glance
- Drug Originator Kyowa Hakko Kirin
- Drug Licenced by NewBridge Pharmaceuticals; Royalty Pharma; Swixx BioPharma; Ultragenyx Pharmaceutical
- Drug Class Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Fibroblast growth factor 23 inhibitors
- USA Patent Applicants KYOWA KIRIN
- USA Patents 1
- BLAs 1
- International Patents 4
Disclaimer